Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
Primary objectives:
1. To comprehensively characterize steady state stereoselective pharmacokinetics of
bupropion and its primary and secondary metabolites in healthy volunteers
2. To prospectively determine the time course (onset), extent and offset of CYP2D6
inhibition in relation to the pharmacokinetic profiles of bupropion and metabolites.
Phase:
Early Phase 1
Details
Lead Sponsor:
Indiana University
Collaborator:
National Institute of General Medical Sciences (NIGMS)